Document
IPR2020-01053, No. 2139-157 Exhibit - Tohen et al, Am J Psychiatry (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2139-157 Exhibit - Tohen et al, Am J Psychiatry (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2079-129 Exhibit - Pareek, Factors Affecting Non Compliance to Psychotropic Drugs ofPatients with Psychosis as Perceived by their Family MembersAttending the Psychiat...
Cite Document
IPR2020-01053, No. 2079-129 Exhibit - Pareek, Factors Affecting Non Compliance to Psychotropic Drugs ofPatients with Psychosis as Perceived by their Family MembersAttending the Psychiatric Outpatient
+ More Snippets
Document
IPR2020-01053, No. 2071-121 Exhibit - O���Day et al, Long term cost effectiveness of atypical antipsychoticsin the treatment of adults with schizophrenia in the US (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2071-121 Exhibit - O���Day et al, Long term cost effectiveness of atypical antipsychoticsin the treatment of adults with schizophrenia in the US (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2044-93 Exhibit - Franklin, Lurasidone for the treatment of bipolar depression an evidence based review (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2044-93 Exhibit - Franklin, Lurasidone for the treatment of bipolar depression an evidence based review (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2048-97 Exhibit - Symbyax�� Label (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2048-97 Exhibit - Symbyax�� Label (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2051-100 Exhibit - Thase, Quetiapine monotherapy for bipolar depression (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2051-100 Exhibit - Thase, Quetiapine monotherapy for bipolar depression (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2046-95 Exhibit - Kane et al Clozapine for the Treatment Resistant Schizophrenia (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2046-95 Exhibit - Kane et al Clozapine for the Treatment Resistant Schizophrenia (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2054-103 Exhibit - Sachs et al, Efficacy and Safety of Adjunctive Oral Ziprasidone forAcute Treatment of Depression in Patients With Bipolar I Disorder (P.T.A.B. Mar. 11, 20...
Cite Document
IPR2020-01053, No. 2054-103 Exhibit - Sachs et al, Efficacy and Safety of Adjunctive Oral Ziprasidone forAcute Treatment of Depression in Patients With Bipolar I Disorder (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2091-140 Exhibit - Comparison of Atypical Antipsychotics (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2091-140 Exhibit - Comparison of Atypical Antipsychotics (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2086-135 Exhibit - Rajagopalan et al, Cost Utility Analysis of Lurasidone VersusAripiprazole in Adults with Schizophrenia (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2086-135 Exhibit - Rajagopalan et al, Cost Utility Analysis of Lurasidone VersusAripiprazole in Adults with Schizophrenia (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2136-154 Exhibit - McElroy et al, Pharmacologic Agents for the Treatment of AcuteBipolar Mania (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2136-154 Exhibit - McElroy et al, Pharmacologic Agents for the Treatment of AcuteBipolar Mania (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2072-122 Exhibit - Dainippon Sumitomo Pharma Co, Ltd, Supplementary Financial Datafor Year Ended March 31, 2014 (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2072-122 Exhibit - Dainippon Sumitomo Pharma Co, Ltd, Supplementary Financial Datafor Year Ended March 31, 2014 (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2087-136 Exhibit - Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatment with Risperidone (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2087-136 Exhibit - Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatment with Risperidone (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2141-159 Exhibit - News Release FDA Approves Once Daily Latuda lurasidoneHCl for Treatment of Patients with Schizophrenia (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2141-159 Exhibit - News Release FDA Approves Once Daily Latuda lurasidoneHCl for Treatment of Patients with Schizophrenia (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2056-105 Exhibit - Stimmel at al, Ziprasidone An Atypical Antipsychotic Drug for theTreatment of Schizophrenia (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2056-105 Exhibit - Stimmel at al, Ziprasidone An Atypical Antipsychotic Drug for theTreatment of Schizophrenia (P.T.A.B. Mar. 11, 2021)
+ More Snippets